R-Tech Ueno Completes Enrollment in Phase 2 Clinical Study for the Agent UF-021
August 30, 2009
R-Tech Ueno, Ltd has announced the completion of subject enrollment in the phase 2 clinical study of 0.15% UF-021 in patients with retinitis pigmentosa. The generic name of UF-021 is isopropyl unoprostone; this is the active ingredient of Rescula™ eye drops. The company expects to complete this trial in the spring of 2010.
Isopropyl unoprostone was launched as a treatment for glaucoma and ocular hypertension; however, other studies have shown some neuroprotective effects of the medication along with improvements in ocular circulation. Other studies have suggested that the agent might improve symptoms of retinitis pigmentosa or even stop progression of the disease.
Read the release.
Comments
Jump down to form below to submit your own comments
